Roche to buy 89bio in deal worth up to $3.5B, picking up MASH drug

Taking stock of the drug industry, from the lab to the medicine chest

September 18, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Sebastien Bozon/AFP via Getty Images STAT+ | Roche to buy 89bio in deal worth up to $3.5B, picking up MASH drug The deal, worth up to $3.5 billion, centers on an experimental treatment called pegozafermin that's in late-stage development. By Andrew Joseph STAT+ | Biogen breaks ground on new Kendall Square headquarters Today's biotech news includes Arsenal Bio layoffs, Sangamo's Fabry gene therapy, and Biogen's 16-story, 580,000-square-foot headquarters. By STAT Staff STAT+ | Sangamo's Fabry therapy partner search looks futile In this week's edition of "Adam's Biotech Scorecard," Adam looks at the prospects for Sangamo and speaks with Porges, now a Wall Street banker. By Adam Feuerstein Adobe STAT+ | NIH outlines new system for awarding research grants to foreign scientists Agency officials say the changes will improve the integrity, accountability, and national security of NIH-funded research By Megan Molteni

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser